文献速递甲状腺疾病

英国威尔士甲状腺激素抵抗β(RTHβ)患者的心血管疾病发病与死亡:一项关联记录队列研究

Cardiovascular morbidity and mortality in patients in Wales, UK with resistance to thyroid hormone β (RTHβ): a linked-record cohort study.
PubMed 文献 · Lancet Diabetes Endocrinol · 2023-07-17

该回顾性队列研究将1997年1月1日至2019年12月31日期间61例经基因确诊的RTHβ患者与2750例年龄性别匹配的对照者关联至威尔士SAIL数据库,分析全因死亡与心血管事件风险。RTHβ患者全因死亡、房颤、心衰及主要不良心血管事件风险均升高,任何不良事件首次发生的中位年龄较对照者提前11年,诊断时FT4≥30 pmol/L与死亡或MACE风险增加相关。抗甲状腺药物、手术或放射性碘腺体消融、或甲状腺素治疗均未能控制甲状腺激素过量。

要点

  • RTHβ患者全因死亡风险升高(HR 2.84,95%CI 1.59-5.08),房颤风险升高(HR 10.56,95%CI 4.72-23.63)。
  • RTHβ患者心衰风险升高(HR 6.35,95%CI 2.26-17.86),MACE风险升高(HR 3.49,95%CI 2.04-5.99)。
  • 诊断时FT4≥30 pmol/L与死亡或MACE风险增加相关,抗甲状腺药物、手术或放射性碘、甲状腺素均未控制激素过量。

核心结论

  • 首次记录到RTHβ患者队列生存期缩短和心血管疾病发病增加,可能由终身心脏暴露于甲状腺激素过量驱动;针对激素抵抗通路的有效治疗可能降低该风险。

研究设计与样本

  • 回顾性队列设计,将基因确诊的RTHβ患者与年龄性别匹配的人群对照者关联至威尔士SAIL数据库中的结局数据。
  • 1997年1月1日至2019年12月31日期间识别61例基因诊断RTHβ患者,匹配2750例对照者。
  • 采用Kaplan-Meier和Cox回归模型分析RTHβ与全因死亡及心血管事件的关联。

主要发现

  • 与对照者相比,RTHβ患者全因死亡风险升高(HR 2.84,95%CI 1.59-5.08)。
  • 与对照者相比,RTHβ患者房颤风险升高(HR 10.56,95%CI 4.72-23.63),心衰风险升高(HR 6.35,95%CI 2.26-17.86)。
  • 与对照者相比,RTHβ患者MACE(包括心血管死亡、急性心肌梗死、心衰或卒中)风险升高(HR 3.49,95%CI 2.04-5.99)。
  • 任何不良事件首次发生的中位年龄在患者中为56岁(95%CI 44-65),较对照者的67岁(95%CI 65-70)提前11年。
  • 立方样条分析显示诊断时FT4浓度与死亡或MACE呈正相关,FT4≥30 pmol/L风险增加;与无干预相比,抗甲状腺药物、手术或放射性碘腺体消融、或甲状腺素治疗均未控制甲状腺激素过量。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Individuals with resistance to thyroid hormone owing to mutations in the thyroid hormone receptor β gene (RTHβ) exhibit impaired tissue sensitivity to thyroid hormones, but retain sensitivity in cardiac tissue. Long-term health and survival outcomes in this rare disorder have not been evaluated. We investigated all-cause mortality and cardiovascular event risk in a cohort of patients with RTHβ, followed-up in UK endocrine clinics. METHODS: In a retrospective cohort design, we linked genetically confirmed patients with RTHβ and age-matched and sex-matched population controls to outcomes in datasets within the Welsh Secure Anonymised Information Linkage (SAIL) Databank. Kaplan-Meier and Cox regression models analysed associations of RTHβ with all-cause mortality and cardiovascular events. FINDINGS: We identified 61 patients with a genetic diagnosis of RTHβ between Jan 1, 1997, and Dec 31, 2019, and matched them with 2750 controls. Compared with controls, patients exhibited increased risks for all-cause mortality (hazard ratio [HR] 2·84, 95% CI 1·59-5·08), atrial fibrillation (10·56, 4·72-23·63), heart failure (HR 6·35, 95% CI 2·26-17·86), and major adverse cardiovascular events (MACE), comprising cardiovascular death, acute myocardial infarction, heart failure, or strokes (HR 3·49, 95% CI 2·04-5·99). The median age of first occurrence of any adverse event was 11 years earlier in patients (56 years, 95% CI 44-65) compared with controls (67 years, 65-70). Cubic spline analyses showed positive associations between FT4 concentrations at diagnosis and mortality or MACE, with FT4 concentration of 30 pmol/L or greater conferring increased risk. Compared with no intervention, treatment with antithyroid drugs, surgery or radioiodine gland ablation, or thyroxine did not control thyroid hormone excess. INTERPRETATION: We have documented reduced survival and increased cardiovascular morbidity in a cohort of patients with RTHβ for the first time. These outcomes might be driven by lifelong cardiac exposure to thyroid hormone excess; and effective therapies, targeting hormone resistant pathways, could potentially curtail this risk. FUNDING: Royal College of Physicians, Wellcome Trust Investigator Award, and NIHR Cambridge Biomedical Research Centre.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Okosieme OE, Usman D, Taylor PN, et al. Cardiovascular morbidity and mortality in patients in Wales, UK with resistance to thyroid hormone β (RTHβ): a linked-record cohort study. Lancet Diabetes Endocrinol. 2023. PMID: 37475119. doi:10.1016/S2213-8587(23)00155-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。